On Feb. 21, 2019, ICON announced that it had acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology.

Founded in 2006, MolecularMD is a recognised leader in the analytical development and clinical validation of molecular diagnostic assays. It offers a comprehensive test menu in immune oncology development from two laboratories in Portland Oregon and Cambridge Massachusetts.